Compare FVCB & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | CABA |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.9M | 319.6M |
| IPO Year | 2018 | 2019 |
| Metric | FVCB | CABA |
|---|---|---|
| Price | $15.64 | $3.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $18.00 | $14.50 |
| AVG Volume (30 Days) | 97.4K | ★ 2.0M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 47.56 | 10.26 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,781,000.00 | N/A |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | ★ 13.87 | N/A |
| 52 Week Low | $9.95 | $1.11 |
| 52 Week High | $16.35 | $3.78 |
| Indicator | FVCB | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 57.85 |
| Support Level | $15.40 | $2.07 |
| Resistance Level | $16.35 | $3.34 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 75.77 | 76.22 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.